Predicting CAR-T therapy outcomes for lymphoma patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study aims to create models that predict how well patients with non-Hodgkin lymphoma will respond to CAR-T cell therapy and how likely they are to have side effects. It may help doctors tailor treatment for people whose lymphoma has not improved or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have non-Hodgkin lymphoma that has come back or did not respond to previous treatment
- Your doctor has decided that CAR-T cell therapy is a good option for you
- You are willing to sign a consent form agreeing to be in the study
- You are willing to agree to have your personal data used for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR T-cell therapy for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see if this therapy can help control the cancer, and the study will monitor side effects and how well the treatment works.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study looks at how well CAR-T cell therapy works in people with blood cancers like lymphoma, ALL, or multiple myeloma, and whether tumor features affect the response. It may help doctors predict who benefits most and how to personalize future care.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.